TRPV1 in gut function, abdominal pain and functional bowel disorders

2005 ◽  
pp. 147-165
Author(s):  
Peter Holzer
Keyword(s):  
Abdominal Pain ◽  
Functional Bowel Disorders ◽  
Gut Function ◽  
Bowel Disorders

III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain

2000 ◽  
Vol 278 (5) ◽  
pp. G670-G676 ◽  
Author(s):  
Lionel Buéno ◽  
Jean Fioramonti ◽  
Rafael Garcia-Villar
Keyword(s):  
Clinical Pharmacology ◽  
Abdominal Pain ◽  
Visceral Pain ◽  
New Drugs ◽  
Receptor Subtypes ◽  
Functional Bowel Disorders ◽  
Afferent Pathways ◽  
Calcitonin Gene ◽  
Bowel Disorders ◽  
Selection Of

Visceral pain is the major cause of consulting in gastroenterology and the principal symptom of functional bowel disorders. This symptom is often associated with gut hypersensitivity to distension. The use of animal models has recently permitted the identification of some mediators supposed to play a pivotal role in the genesis of visceral hypersensitivity. Serotonin, through different receptor subtypes, as well as kinins and calcitonin gene-related peptide, are known to be involved, but other putative transmitters arise and are new potential targets for the development of efficacious treatments. This themes article addresses both physiological and preclinical issues of interest for the selection of active new drugs in regard to the clinical pharmacology of visceral pain.

scholarly journals Functional bowel disorders and functional abdominal pain

Gut ◽  
1999 ◽  
Vol 45 (Supplement 2) ◽  
pp. ii43-ii47 ◽  
Author(s):  
W G Thompson ◽  
G F Longstreth ◽  
D A Drossman ◽  
K W Heaton ◽  
E J Irvine ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Functional Bowel Disorders ◽  
Functional Abdominal Pain ◽  
Bowel Disorders

Irritable bowel syndrome and functional bowel disorders

2010 ◽  
pp. 2384-2388
Author(s):  
D.G. Thompson
Keyword(s):  
Irritable Bowel Syndrome ◽  
Case History ◽  
Medical Advice ◽  
Western World ◽  
Gastrointestinal Function ◽  
Functional Bowel Disorders ◽  
Adequate Explanation ◽  
Gut Function ◽  
Bowel Disorders ◽  
Irritable Bowel

Case History—A 42 yr old woman presenting with increased bowel frequency, loose stools and urgency after treatment of Campylobacter sp.. Symptoms suggestive of disturbed lower gastrointestinal function without adequate explanation are very common in adults in the Western world, up to 15% of whom experience such symptoms at any one time, although most do not seek medical advice. It is not clear whether the symptoms of those individuals who do seek medical help have a different pathophysiological basis from those who do not, and whether the seeking of medical advice is more an indication of a worried individual than of disturbed gut function....

Understanding Functional Bowel Disorders

2012 ◽  
Author(s):  
Jenny Gordon
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Functional Gastrointestinal Disorders ◽  
Gastrointestinal Disorders ◽  
Functional Bowel Disorders ◽  
Abdominal Symptoms ◽  
Bowel Disorders ◽  
Health Nursing ◽  
Functional Bloating ◽  
Irritable Bowel

The aim of this chapter is to provide nurses with the knowledge to be able to assess, manage, and care for people with the group of conditions often described as functional bowel disorders (FBD)—see definitions below—in an evidence-based and person-centred way. The chapter will provide an overview of the causes and impact of FBDs, before exploring best practice to deliver care, as well as to prevent or to minimize further ill-health. Nursing assessments and priorities are highlighted throughout, and the nursing management of the symptoms and common health problems associated with FBDs can be found in Chapters 16, 23, 24, and 25, respectively. This chapter discusses the group of conditions often described as functional bowel disorders (FBDs). The term ‘functional gastrointestinal disorders’ is also used in the literature, but, for the purpose of this book, the term FBDs will be adopted. This refers to a group of disorders that are characterized by chronic gastrointestinal symptoms that currently have an unknown structural or biochemical cause that could explain those symptoms. Rome III is an internationally agreed set of diagnostic criteria and related information on functional gastrointestinal disorders (Longstreth et al., 2006). It includes six major domains for adults: oesophageal; gastro/duodenal; bowel; functional abdominal pain syndrome; biliary; and anorectal. This chapter will cover the FBDs that specifically relate to chronic abdominal symptoms. General abdominal symptoms include functional dyspepsia, non-cardiac chest pain, which may mimic functional abdominal symptoms, chronic abdominal pain, functional constipation, functional diarrhoea, functional bloating, and irritable bowel syndrome (IBS). The chapter will concentrate on irritable bowel syndrome. Coeliac disease and Crohn’s disease are included: to give an understanding of these disorders, and to differentiate between inflammatory and non-inflammatory conditions; to highlight the impact of the symptoms on the people who suffer from them; and to give an insight into the contribution that effective nursing makes. The amount of research and the number of publications concerning FBDs has risen considerably since the mid 1990s, and has contributed to the increasing legitimacy of these conditions as disorders in their own right and not simply by virtue of exclusion of all other possibilities.

Trimebutine: Mechanism of Action, Effects on Gastrointestinal Function and Clinical Results

1997 ◽  
Vol 25 (5) ◽  
pp. 225-246 ◽  
Author(s):  
M Delvaux ◽  
D Wingate
Keyword(s):  
Abdominal Pain ◽  
Contractile Activity ◽  
Opiate Receptors ◽  
Clinical Results ◽  
Phase Iii ◽  
Visceral Sensitivity ◽  
Functional Bowel Disorders ◽  
Gastrointestinal Peptides ◽  
Bowel Disorders ◽  
Irritable Bowel

The actions of trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] on the gastrointestinal tract are mediated via (i) an agonist effect on peripheral μ, k and δ opiate receptors and (ii) release of gastrointestinal peptides such as motilin and modulation of the release of other peptides, including vasoactive intestinal peptide, gastrin and glucagon. Trimebutine accelerates gastric emptying, induces premature phase III of the migrating motor complex in the intestine and modulates the contractile activity of the colon. Recently, trimebutine has also been shown to decrease reflexes induced by distension of the gut lumen in animals and it may therefore modulate visceral sensitivity. Clinically, trimebutine has proved to be effective in the treatment of both acute and chronic abdominal pain in patients with functional bowel disorders, especially irritable bowel syndrome, at doses ranging from 300 to 600 mg/day. It is also effective in children presenting with abdominal pain.

Sign in / Sign up

Export Citation Format

Share Document